Skip to main content

Find Clinical Trials

Home
Conditions
Hypersensitivity

Clinical trial condition

Hypersensitivity

Explore clinical trials studying Hypersensitivity. Study availability and eligibility vary by location and protocol.

6,785 public trials 653 recruiting studies

Refine in advanced search Browse all conditions

Hypersensitivity trial results

Completed

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

NCT06058000

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: The First Hospital of China Medical University Shenyang, Liaoning, China

Dermatology Hospital of Shandong First Medical University Jinan, Shandong, China

View Trial Details

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: Leo Pharma Investigational Site Birmingham, Alabama, United States

Leo Pharma Investigational Site Encino, California, United States

Leo Pharma Investigational Site Los Angeles, California, United States

Leo Pharma Investigational Site Los Angeles, California, United States

View all 31 locations

View Trial Details

Completed

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

NCT06614907

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: Jinan Central Hospital Jinan, Shandong, China

View Trial Details

Completed

Therapist-guided vs Self-guided CBT for AD: Non-inferiority Trial

NCT05517850

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: Centre for psychatry research Stockholm, Stockholm County, Sweden

View Trial Details

Completed

PMCF to Assess Real-life Usage Effectiveness, Safety and Patient Satisfaction of a Range of Hypertonic Seawater-based Decongestant Nasal Sprays

NCT06104332

Conditions: Allergic Rhinitis, Hypersensitivity, Hypersensitivity, Immediate, +8 more
Locations: Alexandra Crevecoeur Honfleur, France

Annie Le Gall Vern-sur-Seiche, France

View Trial Details

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: University of Alabama-Birmingham Birmingham, Alabama, United States

California Dermatology & Clinical Research Institute Encinitas, California, United States

First OC Dermatology Fountain Valley, California, United States

Center for Dermatology Clinical Research Fremont, California, United States

View all 66 locations

View Trial Details

Completed

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

NCT05470114

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: LEO Investigational Site Vienna, Austria

View Trial Details

Completed

ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression

NCT06869382

Conditions: Asthma, Asthma Patients, Bronchial Diseases, +7 more
Locations: Taipei Tzu Chi Hospital New Taipei City, None Selected, Taiwan

View Trial Details

Completed

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: Leo Pharma Investigational Site Fort Smith, Arkansas, United States

LEO Pharma Investigational Site Bakersfield, California, United States

Leo Pharma Investigational Site Beverly Hills, California, United States

Leo Pharma Investigational Site Fountain Valley, California, United States

View all 51 locations

View Trial Details

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861

Conditions: Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
Locations: LEO Pharma Investigational Site Birmingham, Alabama, United States

LEO Pharma Investigational Site Fort Smith, Arkansas, United States

Leo Pharma Investigational Site Fountain Valley, California, United States

LEO Pharma Investigational Site Los Angeles, California, United States

View all 87 locations

View Trial Details